0
0
May 31, 2026
RADNOR, Pa. — A novel medication could soon offer a critical lifeline to millions of people balancing the dangerous combination of high blood pressure and chronic kidney disease (CKD). Mineralys Therapeutics announced new data yesterday, May 30, 2026, at the European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) showing that its investigational drug, lorundrostat, significantly reduces blood pressure while simultaneously protecting compromised kidneys.
The findings, derived from a post hoc analysis of the company’s pivotal Phase 3 Launch-HTN trial, demonstrate statistically significant and clinically meaningful reductions in systolic blood pressure. For individuals struggling with resistant hypertension—blood pressure that remains stubbornly high despite taking multiple medications—the data represents a major therapeutic breakthrough.
The Dangerous Cycle of Hypertension and Kidney Disease
Hypertension and chronic kidney disease share a notoriously destructive relationship. Persistent high blood pressure forces blood to rush through vessels with damaging intensity, scarring the delicate filtering units within the kidneys. As kidney function declines, the organs lose their ability to balance fluids and hormones effectively, which further drives up blood pressure.
The newly released Launch-HTN data suggests that lorundrostat can break this cycle. In the analysis of patients with both CKD and hypertension, the drug cut systolic blood pressure by an impressive 9.6 to 12.2 mmHg.
Crucially, it also reduced albuminuria—the leakage of protein into the urine, which serves as a primary marker of active kidney damage—by 52.2% in patients with elevated baseline protein levels.
In the broader context of the flagship Launch-HTN trial, which evaluated more than 1,000 adults with uncontrolled or resistant hypertension, the benefits were even more pronounced:
-
At 6 weeks: A 50 mg dose of lorundrostat achieved a 16.9 mmHg absolute reduction in systolic blood pressure (a 9.1 mmHg reduction when adjusted against a placebo; p-value < 0.0001).
-
At 12 weeks: The clinical benefit expanded to a 19.0 mmHg absolute reduction (11.7 mmHg placebo-adjusted).
Intercepting the Hormonal Pathway
Lorundrostat achieves these results through an innovative mechanism. It belongs to an emerging class of medications known as aldosterone synthase inhibitors (ASIs).
Aldosterone is a hormone manufactured by the body to regulate salt and water balance. However, when the body produces too much aldosterone, blood pressure spikes, and blood vessels in the kidneys and heart become inflamed and scarred.
Existing therapies, such as standard mineralocorticoid receptor antagonists (MRAs like spironolactone or eplerenone), work by blocking the hormone after it has already been clear-cut and bound to cell receptors. Lorundrostat, by contrast, acts as an upstream interceptor. It shuts down the specific enzyme responsible for producing aldosterone in the first place.
“This mechanism represents a novel approach to treating hypertension, particularly in patients where current therapies fall short,” said Dr. Matthew R. Weir, director of the Division of Nephrology at the University of Maryland Medical Center, who was not involved in the research. “The evidence generated from this trial demonstrates the unique mechanism of action and benefit of lorundrostat in lowering systolic blood pressure and urine albumin-to-creatinine ratio (UACR).”
A Massive Public Health Burden
The potential public health implications of an effective ASI are vast. Data from the Centers for Disease Control and Prevention (CDC) indicates that roughly 37 million American adults—about 15% of the adult population—live with chronic kidney disease. The intersection with hypertension is incredibly dense: more than 21% of adults with high blood pressure are estimated to have concurrent CKD.
For many of these individuals, standard lifestyle modifications and baseline medications are simply not enough. Resistant hypertension affects up to 40% of all CKD patients, leaving them vulnerable to accelerated kidney failure, heart attacks, and strokes.
“Prolonged elevations in blood pressure in patients with compromised renal function can damage the small blood vessels in the kidneys, further reducing their ability to function properly,” Dr. Weir explained, underscoring the urgency for novel interventions.
Navigating Side Effects and Limitations
Despite the enthusiasm surrounding the drug’s efficacy, the medical community is analyzing the data with measured caution. Like any potent cardiovascular medication, lorundrostat carries distinct safety considerations.
Earlier data from the smaller Phase 2 Explore-CKD trial—which paved the way for Phase 3 by showing a 9.25 mmHg reduction in systolic blood pressure compared to just 1.76 mmHg for a placebo—revealed a few warning signs. In that cohort of 59 patients, two individuals on lorundrostat experienced serious adverse events. One patient had to discontinue the drug due to an drop in their estimated glomerular filtration rate (eGFR)—a baseline measure of how well the kidneys filter waste—while another stopped due to a combination of eGFR reduction and elevated potassium levels.
Furthermore, a comprehensive systematic review published in December 2025 flagged a clear trend: while lorundrostat is highly effective at lowering blood pressure, it carries a dose-dependent risk of hyperkalemia (dangerously high blood potassium).
-
At a 50 mg dose, the risk of hyperkalemia increased 6.56-fold.
-
At a 100 mg dose, the risk jumped 10.37-fold.
The minor decrease in mean eGFR seen in the Phase 3 trial (-6.8% with lorundrostat versus -4.6% with a placebo) was deemed expected by the researchers, as blood-pressure-lowering drugs frequently alter kidney filtration pressures initially. However, the systematic review firmly highlighted that long-term cardiovascular outcome trials are still urgently required to prove the drug keeps patients safe over several years.
The Race for Regulatory Approval
The timeline for when patients might actually access this medication is moving rapidly. Mineralys Therapeutics submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), which officially accepted the file in March 2026. The FDA has established a PDUFA target action decision date for December 22, 2026.
The regulatory package is robust, anchored by the positive results of both the Launch-HTN and Advance-HTN trials, alongside an ongoing open-label safety extension study known as Transform-HTN.
However, Mineralys is not alone in this space. Pharmaceutical giant AstraZeneca is hot on its heels with baxdrostat, a competing aldosterone synthase inhibitor acquired via its $1.8 billion purchase of CinCor Pharma. AstraZeneca has deployed a priority review voucher for its FDA filing, positioning it to potentially secure regulatory approval in the second quarter of 2026—months ahead of lorundrostat.
Perspective: What This Means for Everyday Care
If approved, lorundrostat is designed to be utilized as a once-daily, add-on therapy alongside first-line blood pressure medications, including ACE inhibitors, ARBs, and SGLT2 inhibitors.
For clinicians and health-conscious consumers, the drug offers immense promise, but it will require active management. Patients prescribed an ASI will need routine blood draws to monitor their potassium levels and kidney filtration rates, particularly during the first few weeks of starting the treatment.
Independent experts also remind the public to maintain a balanced perspective. The trials conducted thus far have relied heavily on “surrogate markers”—meaning they successfully measured drops in blood pressure numbers and protein spillage, but they have not yet definitively proven that the drug prevents hard clinical endpoints like strokes, heart attacks, or the eventual need for kidney dialysis.
Additionally, regulatory approval is only the first hurdle. Real-world availability will ultimately hinge on commercial pricing, insurance coverage, and how quickly frontline doctors feel comfortable integrating a new class of medicine into their daily practice.
For now, the medical community remains cautiously optimistic. Lorundrostat represents one of the most innovative conceptual advancements in hypertension management in over a decade. While awaiting the FDA’s final verdict this December, patients dealing with resistant high blood pressure and kidney disease should continue working closely with their healthcare teams to optimize their current, proven treatment regimens.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://www.reuters.com/business/healthcare-pharmaceuticals/mineralys-pill-cuts-blood-pressure-kidney-disease-patients-2026-05-30/
